Pfizer sold its $3 billion stake in Haleon

Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
UPDATE: Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale
The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% holding in Haleon in May last year.
Pfizer Sells GBP 2.50 Bln Of Shares In Haleon
Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare
pharmaphorum5d
Pfizer could fetch $15bn for consumer health business
Pfizer is considering selling its consumer healthcare business in a deal that ... one of the largest over the counter products businesses in the world, operating in 90 countries.
What To Expect From PFE Stock In 2025?
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...
Hosted on MSN4mon
Pfizer joins direct-to-consumer drug sales
The new portal could stir up more business for Pfizer drugs, though the company said patients won't be steered to its products and ... and often overwhelming U.S. healthcare system," said Aamir ...
Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
Reuters6d
Pfizer going 'all in' on obesity drug development, CEO Bourla says
Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...
health.economictimes.indiatimes7y
CONSUMER HEALTHCARE
The consumer healthcare division, whose portfolio of products includes also Centrum ... Prior to joining Sanofi, he has worked with Pfizer, LVMH, Heineken and Procter & Gamble in USA and in ...